Enfortumab vedotin
Padcev (enfortumab vedotin) is an antibody pharmaceutical. Enfortumab vedotin was first approved as Padcev on 2019-12-18. It is used to treat urinary bladder neoplasms in the USA. The pharmaceutical is active against nectin-4.
| Trade Name | Padcev |
|---|---|
| Common Name | Enfortumab vedotin |
| Indication | urinary bladder neoplasms |
| Drug Class | Synthetic analogs of the dolastatin series; monoclonal antibodies: fully human, tumors as target |
